1.0 OBJECTIVE:
2.0 SCOPE:
This SOP shall be applicable to the new products which are transferred from R&D or all other product from one site to another site or from contract giver.3.0 RESPONSIBILITY:
R&D Head / Head QA & QC / GM-Production / Unit Head / Contract Giver.4.0 ACCOUNTABILITY:
Head- QA & QC5.0 PROCEDURE:
5.1 Ensure the new product proposal is approved by QA.5.2 Manufacturing license for a commercial production or test license for registration batches for the proposed product shall be obtained from local FDA.
5.3 Technology transfer documents shall be received from R&D or contract giver.
5.4 Analytical method transfer shall be carried out by using approved protocol given by R&D or contract giver.
5.4.1 Upon completion of analytical method transfer, data shall be compiled; report shall be prepared and sent to R&D or contract giver for review.
5.4.2 Method transfer shall be accepted if results are meeting the acceptance criteria.
5.4.3 The same method shall be used during the routine testing performed subsequently.
5.5 Technology transfer document shall include;
5.5.1 Analytical method for API (Active Pharmaceutical Ingredient(s)) inclusive of critical tests like assay, related substances and residual solvents.
5.5.2 In-process analytical methods.
5.5.3 Finished product analytical method inclusive of critical tests like assay, dissolution, related substances and dissolution profile.
5.5.4 Master formula record or process instructions.
5.6 Based on the technology transfer documents and analytical method transfer, the following documents shall be prepared and approved;
5.6.1 Batch manufacturing record
5.6.2 Validation protocol
5.6.3 Batch packaging record
5.6.4 Specification for API, excipients, in-process and finished product.
5.7 For site variation, the existing method/formula as used in the license shall be adopted. Separate technology transfer is not required in case of site transfer products as the same process of manufacturing is adopted on the basis of existing MFR provided by R&D (contract manufacturing department), any difficulty or deviation observed from the process, the specification shall be handled by coordinating with R&D.
5.8 For new products launched at any facility by R&D, analytical method transfer shall be routed through a product-specific protocol.
5.9 In case if any change in approved formula, prior approval from contract giver shall be taken.
5.10 The confirmation batches, registration batches shall be manufactured under the technical guidance of R&D or contract giver as per approved validation protocol or batch manufacturing record.
5.11 Necessary training shall be provided to the concerned people.
5.12 In case of any deviation from the approved protocol or BMR, deviation control procedure shall be followed.
6.0 ABBREVIATIONS:
6.1 SOP: Standard Operating Procedure6.2 QA: Quality Assurance
6.3 QC: Quality Control
6.4 R&D: Research and Development
6.5 FDA: Food and Drug Administration
6.6 API: Active Pharmaceutical Ingredient
6.7 MFR: Master Formula Record
6.8 BMR: Batch Manufacturing Record
Get ready to use editable documents in MS-Word FormatView List
excellent work.
ReplyDeletesir could you share SOP/reference for % yield calculation for oral tablet.
sir , do you have any update/ revisions on drug regulatory affairs in CIS & Latin countries.
ReplyDeleteSir,Excellent
ReplyDeletePlease include the types of technology transfer to be followed
ReplyDelete